209 related articles for article (PubMed ID: 27633411)
21. How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?
Soultati A; Stares M; Swanton C; Larkin J; Turajlic S
Curr Opin Urol; 2015 Sep; 25(5):358-66. PubMed ID: 26125509
[TBL] [Abstract][Full Text] [Related]
22. The pathway to biomarker discovery: carbonic anhydrase IX and the prediction of immune responsiveness.
Panelli MC; Wang E; Marincola FM
Clin Cancer Res; 2005 May; 11(10):3601-3. PubMed ID: 15897553
[No Abstract] [Full Text] [Related]
23. [Papillary renal cell carcinoma and tumor biology. A multicenter project with "tissue microarray" (TMA)].
Herrmann E; Wülfing C; Hartmann A
Urologe A; 2007 Sep; 46(9):1175-6. PubMed ID: 17646959
[No Abstract] [Full Text] [Related]
24. Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies.
Golshayan AR; Brick AJ; Choueiri TK
Future Oncol; 2008 Feb; 4(1):85-92. PubMed ID: 18241003
[TBL] [Abstract][Full Text] [Related]
25. Type 1 and 2 papillary renal cancers are genetically distinct.
Balakrishnan VS
Lancet Oncol; 2015 Dec; 16(16):e594. PubMed ID: 26596671
[No Abstract] [Full Text] [Related]
26. Hereditary Renal Cell Carcinoma Syndromes: Clinical, Pathologic, and Genetic Features.
Adeniran AJ; Shuch B; Humphrey PA
Am J Surg Pathol; 2015 Dec; 39(12):e1-e18. PubMed ID: 26559379
[TBL] [Abstract][Full Text] [Related]
27. Maurie Markman on the Groundbreaking TAPUR Trial.
Markman M
Oncology (Williston Park); 2017 Mar; 31(3):158, 168. PubMed ID: 28299751
[No Abstract] [Full Text] [Related]
28. Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan-omics precision.
Hsieh JJ; Le V; Cao D; Cheng EH; Creighton CJ
J Pathol; 2018 Apr; 244(5):525-537. PubMed ID: 29266437
[TBL] [Abstract][Full Text] [Related]
29. The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.
Buti S; Bersanelli M
Future Oncol; 2016 Sep; 12(18):2061-3. PubMed ID: 27168416
[No Abstract] [Full Text] [Related]
30. Population-Based Study to Determine the Health System Costs of Using the 21-Gene Assay.
Mittmann N; Earle CC; Cheng SY; Julian JA; Rahman F; Seung SJ; Levine MN
J Clin Oncol; 2018 Jan; 36(3):238-243. PubMed ID: 29193984
[TBL] [Abstract][Full Text] [Related]
31. Correcting overall survival for the impact of crossover via a rank-preserving structural failure time (RPSFT) model in the RECORD-1 trial of everolimus in metastatic renal-cell carcinoma.
Korhonen P; Zuber E; Branson M; Hollaender N; Yateman N; Katiskalahti T; Lebwohl D; Haas T
J Biopharm Stat; 2012; 22(6):1258-71. PubMed ID: 23075021
[TBL] [Abstract][Full Text] [Related]
32. [Third-line therapy for metastasized renal cell carcinoma: a randomized, multicenter non-blinded phase III study to compare safety and effectiveness of TF1258 versus sorafenib in patients with metastasized renal cell carcinoma following failure of antiangiogenic (VEGF targeted and mTOR inhibition) therapy (GOLD-AN 31/11 of the Working Group Urological Oncology)].
Rexer H
Urologe A; 2011 Oct; 50(10):1319-21. PubMed ID: 21976121
[No Abstract] [Full Text] [Related]
33. New Math on Drug Cost-Effectiveness.
Bach PB
N Engl J Med; 2015 Nov; 373(19):1797-9. PubMed ID: 26535510
[No Abstract] [Full Text] [Related]
34. The Costly War Against Cancer Treatment: The Example of Metastatic Renal Cell Carcinoma in Portugal.
Barata PC; Alpuim Costa D; Passos Coelho JL; Da Luz R
Acta Med Port; 2018 Aug; 31(7-8):373-375. PubMed ID: 30189164
[No Abstract] [Full Text] [Related]
35. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma.
Remák E; Charbonneau C; Négrier S; Kim ST; Motzer RJ
J Clin Oncol; 2008 Aug; 26(24):3995-4000. PubMed ID: 18711190
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of sunitinib in metastatic renal cell carcinoma.
Purmonen TT
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):383-93. PubMed ID: 21831017
[TBL] [Abstract][Full Text] [Related]
37. Kidney cancer: not a single disease.
Pospihalj B; Zamparese R; Mazzucchelli R; Morichetti D
Anal Quant Cytol Histol; 2007 Dec; 29(6):377-9. PubMed ID: 18228653
[No Abstract] [Full Text] [Related]
38. Prognostic implications of polymorphisms and interleukin-2 therapy for renal cell carcinoma.
Gardner TA; Logan T
J Urol; 2009 Aug; 182(2):425-6. PubMed ID: 19524946
[No Abstract] [Full Text] [Related]
39. Molecular genetic events associated with renal cell carninoma and its implication to treatment by molecular target therapy.
Kishida T; Yao M; Uemura H; Ohlmann C; Tomita Y; Bukowski RM; Naito S
Int J Urol; 2010 Mar; 17(3):198-205. PubMed ID: 20409215
[No Abstract] [Full Text] [Related]
40. SnapShot: Renal Cell Carcinoma.
Turajlic S; Larkin J; Swanton C
Cell; 2015 Dec; 163(6):1556-1556.e1. PubMed ID: 26638079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
